Lansoprazole Capsule, Delayed Release
Product Images NDC 68071-2274

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 68071-2274). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2274 6)

Packaging label for Lansoprazole 15 mg delayed-release capsules by NuCare Pharmaceuticals, Inc. The label indicates a bottle containing 60 capsules. The capsules are described as oblong with a green opaque cap and white opaque body, imprinted with 'LIFESTAR' on the cap and '806' on the body. The label includes dosage instructions, warnings to keep out of reach of children, and storage temperature guidelines.*

FDA Label Image

F53ca2be-a290-4157-ad95-d24dfe3344f9-01 (F53ca2be A290 4157 Ad95 D24dfe3344f9 01)

Chemical structure of lansoprazole, depicting its molecular arrangement including a benzimidazole ring and a substituted pyridine ring with a sulfoxide group connecting the two.*

FDA Label Image

F53ca2be-a290-4157-ad95-d24dfe3344f9-02 (F53ca2be A290 4157 Ad95 D24dfe3344f9 02)

A line graph showing the mean severity of day heartburn by study day for evaluable patients, with a scale from 0 (none) to 3 (severe) on the y-axis and days from start of treatment on the x-axis (ranging from -5 to 60). It compares placebo, lansoprazole 15 mg QD, and lansoprazole 30 mg QD groups, illustrating decreases in heartburn severity over time for the lansoprazole groups compared to placebo.*

FDA Label Image

F53ca2be-a290-4157-ad95-d24dfe3344f9-03 (F53ca2be A290 4157 Ad95 D24dfe3344f9 03)

Line graph showing the mean severity of night heartburn by study day for evaluable patients, comparing placebo, Lansoprazole 15 mg once daily, and Lansoprazole 30 mg once daily. The y-axis represents mean severity on a scale from 0 (none) to 3 (severe). The x-axis shows days from the start of treatment, ranging from -5 to 60 days. Both Lansoprazole groups show a greater reduction in heartburn severity over time compared to placebo.*

FDA Label Image

F53ca2be-a290-4157-ad95-d24dfe3344f9-06 (F53ca2be A290 4157 Ad95 D24dfe3344f9 1)

Lansoprazole 15 mg delayed release capsules packaging from NuCare Pharmaceuticals, Inc. The white carton shows the brand and generic name on the front along with strength and dosage form. The labeler name and NDC 68071-2274 are also displayed. Intended for oral use.*

FDA Label Image

F53ca2be-a290-4157-ad95-d24dfe3344f9-07 (F53ca2be A290 4157 Ad95 D24dfe3344f9 2)

Lansoprazole 15 mg delayed release oral capsules packaging from NuCare Pharmaceuticals, Inc. The carton is white with orange and yellow patterns on the side and text in black and orange. The label includes the product name, strength, dosage form, and the labeler information.*

FDA Label Image

Image (F53ca2be A290 4157 Ad95 D24dfe3344f9 6)

Lansoprazole 15 mg delayed-release capsules carton by NuCare Pharmaceuticals, Inc. The front panel shows the product name, dosage strength, dosage form, oral route, quantity count of 30 capsules, and the NDC number 68071-2274. The box is primarily white with blue and orange elements, including the Lifestar brand logo in the upper right corner.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.